Fremont, CA, United States of America

Subhashini Arimilli

This inventor holds 1 USPTO granted patent. Top assignee: Corixa Corporation. Active years: 2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Subhashini Arimilli. Retrieved from https://idiyas.com/inventor/subhashini-arimilli-ow7h6qw6

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Subhashini Arimilli: Innovator in Immunology

Introduction

Subhashini Arimilli is a prominent inventor based in Fremont, CA. She has made significant contributions to the field of immunology, particularly through her innovative research and development of immunogenic oligopeptides.

Latest Patents

Subhashini holds 1 patent for her invention titled "Chemokine receptor peptide for inducing an immune response." This invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods aimed at treating and preventing inflammatory responses.

Career Highlights

Subhashini is currently employed at Corixa Corporation, where she continues to advance her research in immunology. Her work has been instrumental in developing new therapeutic strategies that leverage the immune system.

Collaborations

Some of her notable coworkers include Maureen C Howard and Shrikant Deshpande, who have collaborated with her on various projects within the company.

Conclusion

Subhashini Arimilli's contributions to immunology through her innovative patents and collaborative efforts highlight her role as a key figure in advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…